Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
Latest Information Update: 16 Oct 2019
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 14 Oct 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2015 Planned End Date changed from 1 Aug 2018 to 1 Apr 2020 as reported by ClinicalTrials.gov.